ahlam1399
05-22-2015, 04:56 PM
Merck follows Bristol with EU green light for immune cancer drug
(Reuters) - European regulators have recommended approval of Merck & Co Inc's immune system-boosting cancer drug Keytruda, following a similar green light last month for Bristol-Myers Squibb Co's rival product Opdivo.http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/468d641b/sc/21/mf.gif?resize=1%2C1
http://da.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/rc/1/rc.img (http://da.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/rc/1/rc.htm)
http://da.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/rc/2/rc.img (http://da.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/rc/2/rc.htm)
http://da.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/rc/3/rc.img (http://da.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/rc/3/rc.htm)
http://da.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/a2.img (http://da.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/a2.htm)
http://adchoice.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/ach.img (http://adchoice.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/ach.htm)http://pi.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/a2t.imghttp://pi2.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/a2t2.imghttp://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=3gRlBZcYI9A:Af88w2PDn-8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=3gRlBZcYI9A:Af88w2PDn-8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=3gRlBZcYI9A:Af88w2PDn-8:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=3gRlBZcYI9A:Af88w2PDn-8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=3gRlBZcYI9A:Af88w2PDn-8:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/3gRlBZcYI9A
(Reuters) - European regulators have recommended approval of Merck & Co Inc's immune system-boosting cancer drug Keytruda, following a similar green light last month for Bristol-Myers Squibb Co's rival product Opdivo.http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/468d641b/sc/21/mf.gif?resize=1%2C1
http://da.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/rc/1/rc.img (http://da.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/rc/1/rc.htm)
http://da.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/rc/2/rc.img (http://da.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/rc/2/rc.htm)
http://da.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/rc/3/rc.img (http://da.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/rc/3/rc.htm)
http://da.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/a2.img (http://da.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/a2.htm)
http://adchoice.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/ach.img (http://adchoice.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/ach.htm)http://pi.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/a2t.imghttp://pi2.feedsportal.com/r/228766219591/u/49/f/654207/c/35217/s/468d641b/sc/21/a2t2.imghttp://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=3gRlBZcYI9A:Af88w2PDn-8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=3gRlBZcYI9A:Af88w2PDn-8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=3gRlBZcYI9A:Af88w2PDn-8:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=3gRlBZcYI9A:Af88w2PDn-8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=3gRlBZcYI9A:Af88w2PDn-8:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/3gRlBZcYI9A